Legend Biotech
Legend Biotech is the Chinese-origin developer of Carvykti, the most effective myeloma CAR-T, with J&J.
Ciltacabtagene autoleucel; solid-tumour CAR-T (CLDN18.2 LB1908, DLL3).
CARTITUDE-4 is the first randomised trial to show that a CAR-T improves survival in myeloma, and it moved cilta-cel into second-line use (FDA approval 2024). For patients whose disease returns after first-line lenalidomide, a one-off cell therapy now competes with continuous drug combinations. Capacity, cost and the need for bridging therapy still limit who actually receives it.
CARTITUDE-1 showed that a single CAR-T infusion can put late-stage myeloma into deep, multi-year remission, leading to FDA approval of cilta-cel in 2022 for heavily pretreated disease. It set the efficacy bar for BCMA-directed therapy and motivated moving CAR-T earlier (CARTITUDE-4). Late neurological toxicity and secondary malignancies remain the safety questions.
Pages like this
not linked directly; found by shared links- TrialCARTITUDE-1
Shares CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma, Ciltacabtagene autoleucel, Multiple myeloma.
- TrialCARTITUDE-5
Shares CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy, Ciltacabtagene autoleucel, Multiple myeloma.
- TrialCARTITUDE-4
Shares CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy, Ciltacabtagene autoleucel, Multiple myeloma.
- IdeaOne CAR-T infusion instead of autologous transplant
- ProductPomalidomide
Shares CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy, Multiple myeloma.
- PersonSaad Z. Usmani
Shares CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma, Multiple myeloma.
- TargetGPRC5D
Shares Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Multiple myeloma.
- InstitutionIUCT Oncopole – Institut Universitaire du Cancer de Toulouse